January 31, 2014 – Tarrytown, New York. – PsychoGenics Inc. announced today that it has obtained licenses to the rTg4510 tauopathy mouse from Mayo Clinic and TET Systems GmbH & Co. KG (TET Systems). The rTg4510 mouse expresses the P301L mutation in the tau gene associated with frontotemporal dementia and Parkinsonism linked to chromosome 17. Transgene expression in this model is induced via the tetracycline-operon responsive element (licensed from TET Systems) and is reversibly suppressed after treatment with doxycycline.
